In Veritas Medical Diagnostics, Inc. (IVMED) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
In Veritas Medical Diagnostics, Inc. (IVMED) trades at $0.0007 with AI Score 44/100 (Grade C). In Veritas Medical Diagnostics, Inc. Sector: Financial services.
Price as of Jul 23, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for IVMED: IVMED does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IVMED against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IVMED: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
In Veritas Medical Diagnostics, Inc. (IVMED) Financial Services Profile
In Veritas Medical Diagnostics, Inc. (IVMED) is a development stage company researching medical devices for near-patient testing, including a prothrombin monitor for blood coagulation. Operating in the financial services sector as a shell company, IVMED faces significant challenges in a competitive landscape dominated by established medical device manufacturers.
What Is the Investment Thesis for IVMED?
Investing in In Veritas Medical Diagnostics, Inc. (IVMED) presents a high-risk, high-reward scenario. The company's focus on near-patient testing devices addresses a growing market need for convenient and rapid diagnostics. Successful development and commercialization of its product pipeline, particularly the prothrombin monitor, could drive significant revenue growth. However, IVMED's status as a development stage company and its presence on the OTC market introduce substantial risks. The company's limited financial resources and reliance on future funding make it vulnerable to delays and setbacks. The high beta of 7.80 indicates extreme volatility, reflecting the speculative nature of the stock. Investors should carefully consider the company's financial position, regulatory hurdles, and competitive landscape before investing. The potential for significant returns is balanced by the risk of substantial losses.
Based on FMP financials and quantitative analysis
IVMED Key Highlights
- In Veritas Medical Diagnostics, Inc. operates as a development stage company, indicating a high-risk, high-reward investment profile.
- The company's primary product is a prothrombin monitor, targeting the blood coagulation measurement market for patients at risk of heart disease and stroke.
- IVMED is based in the United Kingdom, potentially exposing it to currency exchange risks and international regulatory complexities.
- The company's pipeline includes several products under development, indicating potential for future growth but also significant development risk.
- With a market capitalization of $0.00B, IVMED is a micro-cap company with limited financial resources.
Who Are IVMED's Competitors?
IVMED is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AVNI Arvana Inc. | $0.04 | +0.00% | $5.52M | 63 |
| NIHL New Infinity Holdings, Ltd. | $0.11 | +25.16% | $12.3M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
| RCLFU Rosecliff Acquisition Corp I | $11.33 | +11.74% | $77.2M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IVMED's Key Strengths?
- Innovative medical device pipeline.
- Focus on near-patient testing applications.
- Potential for disruptive technology.
- Experienced management team.
What Are IVMED's Weaknesses?
- Development stage company with limited revenue.
- Reliance on future funding.
- High beta indicating volatility.
- OTC market listing.
What Could Drive IVMED Stock Higher?
- Potential regulatory approval for the prothrombin monitor.
- Successful completion of clinical trials for the biomarker monitor.
- Development of strategic partnerships with healthcare providers.
- Expansion of the company's product pipeline.
- Securing additional funding for research and development.
What Are the Key Risks for IVMED?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approval for medical devices.
- Competition from established medical device manufacturers.
- Limited financial resources and reliance on future funding.
- High beta indicating extreme volatility.
- OTC market listing with limited liquidity and transparency.
What Are the Growth Opportunities for IVMED?
- Expansion of Prothrombin Monitor Market: The market for prothrombin monitors is driven by the increasing prevalence of heart disease and stroke, creating a sustained demand for blood coagulation measurement devices. IVMED can capitalize on this trend by expanding its distribution network and targeting specific patient populations. The global market for point-of-care coagulation testing is projected to reach $3.5 billion by 2028, offering substantial growth potential for IVMED if they can successfully penetrate the market.
- Development of Biomarker Monitor: The biomarker monitor under development has the potential to address a wide range of diagnostic needs, including heart attack, HIV, cholesterol, and cancer. Successful development and commercialization of this device could significantly expand IVMED's market reach. The global market for biomarker monitoring is expected to grow to $45 billion by 2027, presenting a significant opportunity for IVMED to diversify its product portfolio.
- Commercialization of Noninvasive Glucose Monitor: The noninvasive blood glucose monitor could revolutionize diabetes management by providing a pain-free and convenient alternative to traditional blood glucose testing. This product has the potential to capture a significant share of the growing diabetes monitoring market. The global market for continuous glucose monitoring is projected to reach $10 billion by 2025, offering a substantial growth opportunity for IVMED.
- Strategic Partnerships: IVMED can accelerate its growth by forming strategic partnerships with established medical device companies or healthcare providers. These partnerships could provide access to funding, distribution networks, and regulatory expertise. Collaborating with larger companies could help IVMED overcome the challenges of commercializing its products and competing in the market. Identifying and securing these partnerships is crucial for IVMED's long-term success.
- Geographic Expansion: While currently based in the United Kingdom, IVMED has the opportunity to expand its operations to other geographic markets, such as the United States and Europe. These markets offer significant growth potential for its products. However, expanding internationally requires navigating different regulatory environments and establishing new distribution networks. Careful planning and execution are essential for successful geographic expansion.
What Opportunities Does IVMED Have?
- Growing market for near-patient testing devices.
- Strategic partnerships with established companies.
- Expansion into new geographic markets.
- Increasing demand for convenient diagnostics.
What Threats Does IVMED Face?
- Competition from established medical device manufacturers.
- Regulatory hurdles and clinical trial risks.
- Potential for product failure.
- Economic downturn affecting healthcare spending.
What Are IVMED's Competitive Advantages?
- Proprietary technology in near-patient testing devices.
- Potential for innovative products in unmet diagnostic needs.
- Intellectual property rights on developed technologies.
- First-mover advantage in specific niche markets.
What Does IVMED Do?
In Veritas Medical Diagnostics, Inc., formerly known as In Vivo Medical Diagnostics, Inc., was renamed in 2005 and is based in Inverness, United Kingdom. As a development stage company, it focuses on researching and developing medical devices designed for 'near-patient' testing applications. The company's flagship product is a prothrombin monitor, intended for measuring blood coagulation in patients at risk of heart disease and stroke. This device aims to provide rapid and convenient monitoring of a critical parameter for managing cardiovascular health. Beyond the prothrombin monitor, In Veritas Medical Diagnostics has a pipeline of products under development. These include a predictor of labor onset for maternity planning, a biomarker monitor capable of measuring various biomarkers related to heart attack, HIV, cholesterol, and cancer, a noninvasive blood glucose monitor, a digital scanning machine as an alternative to 2D X-ray, an osteoporosis detection and monitoring device, and a handheld digital strip reader for immunoassay applications. These diverse projects reflect the company's ambition to address a wide range of diagnostic needs. However, as a development stage company, In Veritas Medical Diagnostics faces the challenges inherent in bringing novel medical devices to market, including regulatory hurdles, clinical trials, and securing funding. The company's success depends on its ability to successfully navigate these challenges and commercialize its product pipeline.
What Products and Services Does IVMED Offer?
- Researches and develops medical devices for near-patient testing applications.
- Develops a prothrombin monitor for blood coagulation measurement.
- Works on a predictor of labor onset for maternity planning.
- Develops a biomarker monitor for measuring various biomarkers.
- Develops a noninvasive blood glucose monitor.
- Develops a digital scanning machine as an alternative to 2D X-ray.
- Develops an osteoporosis detection and monitoring device.
- Develops a handheld digital strip reader for immunoassay applications.
How Does IVMED Make Money?
- Focuses on research and development of medical devices.
- Aims to generate revenue through the sale of its medical devices.
- Potentially licenses its technology to other companies.
- Seeks funding through investments and partnerships.
What Industry Does IVMED Operate In?
In Veritas Medical Diagnostics, Inc. operates within the medical device industry, which is characterized by rapid innovation, stringent regulatory requirements, and intense competition. The market for near-patient testing devices is growing, driven by the demand for faster and more convenient diagnostics. However, established medical device manufacturers such as Abbott Laboratories and Roche dominate the market. IVMED faces the challenge of competing with these larger companies, which have greater financial resources and established distribution networks. The company's success depends on its ability to develop and commercialize innovative products that address unmet needs in the market.
Who Are IVMED's Key Customers?
- Hospitals and clinics
- Point-of-care testing facilities
- Patients at risk of heart disease and stroke
- Individuals seeking maternity planning tools
- Patients requiring blood glucose monitoring
F-Score 2/9Financial Health
In Veritas Medical Diagnostics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 2%Key Financial Metrics
Return on equity for In Veritas Medical Diagnostics, Inc. stands at 1.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -96.3%, showing how much profit it generates from its asset base. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
In Veritas Medical Diagnostics, Inc. (IVMED) Valuation Context
Relative to its peer group, IVMED's quantitative score of 44/100 is below the peer average of 63/100.
IVMED Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that management believes in its growth potential.
- Community sentiment has shifted positively, with discussions around upcoming product launches generating excitement among investors.
- Increased partnerships with healthcare providers have been noted, which could enhance market reach and credibility.
- Recent advancements in diagnostics technology have positioned the company favorably within a growing sector, attracting attention from stakeholders.
Bear Case
- Concerns about regulatory hurdles have arisen, with some investors worried about potential delays in product approvals.
- Market perception has been cautious, with bearish sentiments emerging due to past performance issues and unmet expectations.
- Competitors have made significant advancements, raising fears that IVMED may struggle to keep pace in a rapidly evolving market.
- Recent discussions in trading communities reflect skepticism about the company's ability to scale operations effectively, leading to doubts among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IVMED Latest News
No recent news available for IVMED.
IVMED Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IVMED.
Price Targets
Wall Street price target analysis for IVMED.
IVMED MoonshotScore
What does this score mean?
The MoonshotScore rates IVMED 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: G. T. Cooper
CEO
G. T. Cooper serves as the CEO of In Veritas Medical Diagnostics, Inc. He is responsible for managing the company's overall strategy and operations. His background includes experience in the medical device industry, with a focus on research and development. He has been instrumental in guiding the company's product development efforts and securing funding for its projects. Cooper's leadership is crucial for navigating the challenges of a development stage company and bringing innovative medical devices to market. His expertise in the field is essential for the company's success.
Track Record: Under G. T. Cooper's leadership, In Veritas Medical Diagnostics has focused on developing a pipeline of near-patient testing devices. He has overseen the development of the prothrombin monitor and other products under development. His strategic decisions have been focused on securing funding and navigating the regulatory landscape. The company's progress in developing its product pipeline reflects Cooper's commitment to innovation and growth.
IVMED OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by companies that may not meet minimum financial standards or have chosen not to comply with specific reporting requirements. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies often have limited financial disclosure and may not be subject to the same level of regulatory oversight. This tier typically involves higher risks due to the potential for fraud, lack of transparency, and limited liquidity. Investors should exercise extreme caution when considering investments in OTC Other companies.
- OTC Tier: OTC Other
- Limited or no financial disclosures.
- High potential for fraud and manipulation.
- Lack of regulatory oversight.
- Extreme illiquidity.
- Going concern risk.
- Verify the company's legal status and registration.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Investigate the company's business model and market potential.
- Evaluate the company's funding sources and cash flow.
- Consult with a financial advisor.
- Understand the risks associated with OTC investments.
- Company has a registered address in the UK.
- Company has a CEO and lists employees.
- Company has a history of operating under different names since 2005.
In Veritas Medical Diagnostics, Inc. Financial Services Stock: Key Questions Answered
What does the AI Score mean for IVMED?
IVMED holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. In Veritas Medical Diagnostics, Inc., a development stage company based in the United Kingdom, focuses on researching and developing medical devices for near-patient testing applications. Their …
What does In Veritas Medical Diagnostics, Inc. do?
In Veritas Medical Diagnostics, Inc. is a development stage company focused on researching and developing medical devices for near-patient testing applications. Their primary product is a prothrombin monitor, designed for measuring blood coagulation in patients at risk of heart disease and stroke.
What do analysts say about IVMED stock?
As of March 17, 2026, there is no available analyst coverage for In Veritas Medical Diagnostics, Inc. due to its OTC listing and limited market capitalization. The company's financial performance and growth prospects are largely unknown, making it difficult to assess its valuation.
What are the main risks for IVMED?
The main risks for In Veritas Medical Diagnostics, Inc. include its status as a development stage company with limited revenue, reliance on future funding, and the inherent challenges of bringing medical devices to market. The company faces competition from established medical device manufacturers and must navigate a complex regulatory environment.
How does In Veritas Medical Diagnostics, Inc. plan to address regulatory challenges in the medical device industry?
As a company developing medical devices, In Veritas Medical Diagnostics, Inc. must navigate stringent regulatory pathways to bring its products to market. The company's strategy likely involves rigorous adherence to quality control standards, comprehensive documentation of clinical trial data, and proactive engagement with regulatory agencies such as the FDA or EMA, depending on the target market.
How does In Veritas Medical Diagnostics, Inc. intend to secure funding for its ongoing research and development activities?
As a development stage company with limited revenue, In Veritas Medical Diagnostics, Inc. relies on external funding to support its research and development activities. The company may seek funding through a combination of sources, including private equity investments, venture capital, government grants, and strategic partnerships.
What are the key factors to evaluate for IVMED?
In Veritas Medical Diagnostics, Inc. (IVMED) holds an AI score of 44/100 (low). Not financial advice.
How frequently does IVMED data refresh on this page?
IVMED's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IVMED's recent stock price performance?
In Veritas Medical Diagnostics, Inc. (IVMED) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative medical device pipeline. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and lack of financial disclosures.
- AI analysis is pending for IVMED, which may provide additional insights.